Sort
82,697 grants matching “vaccine development”
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Intervention
$1,857,998John D Roback · Emory University · P01 · FY2009 · HL
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
$1,857,725Estuardo Aguilar-Cordova · Advantagene, Inc · R44 · FY2013 · CA
Seattle-Lausanne Clinical Trials Unit
$1,857,698Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2024 · AI
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env
$1,857,587Shan Lu · Univ Of Massachusetts Med Sch Worcester · P01 · FY2009 · AI
Seattle-Lausanne Clinical Trials Unit
$1,857,247Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2023 · AI
Subcellular protein localization in B. subtilis
$1,857,140Kumaran Ramamurthi · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors receiving Follow-Up Care in Pediatric Oncology Practices: A Cluster-Randomized Trial
$1,856,897Wendy Landier · University Of Alabama At Birmingham · U01 · FY2020 · CA
Simian Vaccine Evaluation Unit: Operation of a Nonhuman Primate Breeding Colony
$1,856,713Francois Villinger · University Of Louisiana At Lafayette · N01 · FY2022 · AI
Alabama-Clinical Trials Unit
$1,856,693Michael S. Saag · University Of Alabama At Birmingham · UM1 · FY2012 · AI
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
$1,855,534Ruth Margrit Ruprecht · University Of Louisiana At Lafayette · U19 · FY2020 · AI
CAPRISA Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment
$1,855,454Quarraisha Abdool Karim · Centre/Aids Programme/Res/South Africa · UM1 · FY2018 · AI
Developing Vaccine Candidates for the SARS Coronavirus
$1,854,836Ralph S Baric · Univ Of North Carolina Chapel Hill · P01 · FY2008 · AI
Role of the microbiota in immunity
$1,854,105Yasmine Belkaid · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Resistance to MTB infection in HIV infected individuals in Uganda and S. Africa
$1,853,980W. Henry Henry Boom · Case Western Reserve University · R01 · FY2020 · AI
T Cell Memory to Pathogens: Generation and Function
$1,853,585Susan L Swain · Univ Of Massachusetts Med Sch Worcester · P01 · FY2011 · AI
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env
$1,852,576Shan Lu · Univ Of Massachusetts Med Sch Worcester · P01 · FY2010 · AI
Virus-Host Interactions: Induction and Evasion of Host Innate Immunity
$1,852,431Sonja Best · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Rapid response for pandemics: single cell sequencing and deep learning to predict antibody sequences against an emerging antigen
$1,851,627Animesh Ray · Keck Graduate Inst Of Applied Life Scis · R01 · FY2021 · AI
Long-term ocular sequelae and biological determinants of post-acute Ebola virus disease
$1,850,974John Daniel Kelly · Northern California Institute/Res/Edu · U01 · FY2025 · EY
Entry and replication of positive-sense, RNA viruses
$1,850,932Joseph Marcotrigiano · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Immunologic &Virologic Features of Early HIV Infection
$1,850,423University Of California San Francisco · U01 · FY2003 · AI
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)
$1,849,047Michael G Agadjanyan · Institute For Molecular Medicine · U01 · FY2025 · AG
Combination immunotherapy with gene modified CD4 and CD8 T cells and stem cells
$1,848,744Carl H. June · University Of Pennsylvania · U19 · FY2010 · AI
Integrase Defective Lentiviral Vector (IDLV)-ENV Immunogen Strategy for an HIV Vaccine
$1,848,708Mary E. Klotman · Duke University · P01 · FY2015 · AI
HIV/AIDS Vaccine Development
$1,848,705John Mascola · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI